Benzothiophene PPARδ Activator Enhances Binding Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current activators of peroxisome proliferator-activated receptors (PPAR) lack specificity and efficacy in activating PPARδ, which is crucial for treating metabolic and inflammatory diseases, as existing compounds have structural differences that affect their binding affinity and therapeutic outcomes.
Innovation Solution
Development of novel compounds with specific structural features, such as the presence of a benzothiophene ring and a unique linker, which enhance the activation of PPARδ by improving the binding affinity and selectivity compared to existing compounds like GW-501516.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PPAR activators (e.g., GW-501516) are used, then general PPAR activation is achieved, but specificity for PPARδ is insufficient and binding affinity is limited
Solution Approach 1:
The patent applies local quality by introducing a benzothiophene ring structure at a specific position in the molecule, which provides selective binding affinity for PPARδ. This localized structural modification enhances the interaction with the PPARδ receptor while maintaining overall molecular functionality, thereby improving both binding affinity and selectivity simultaneously
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure parameters of the activator molecules. Specifically, it changes the core structure from conventional rings to a benzothiophene ring system, which alters the binding characteristics and enhances selectivity for PPARδ. This structural parameter modification enables the compound to achieve high binding affinity and specific activation of PPARδ
2Reliability
If conventional PPAR activators are used, then transcription activation is achieved, but therapeutic efficacy for metabolic and inflammatory diseases is insufficient
Solution Approach 1:
The patent utilizes parameter changes by optimizing the molecular structure to enhance transcription activation capability. The benzothiophene ring structure and specific linker configurations are designed to increase the potency of PPARδ activation, thereby improving therapeutic efficacy for metabolic and inflammatory diseases while maintaining strong transcriptional activity
Data Source
AI summary
A compound represented by the formula (I) or a pharmacologically acceptable salt thereof is used as an activator of PPAR. wherein each of R1 and R2 is hydrogen, C1-8 alkyl, C1-8 alkyl substituted with halogen, or the like; each of R3, R4, R5, and R6 is hydrogen, C1-8 alkyl, or the like; X is sulfur or the like; Y is oxygen, a bond, or the like; p is 0 or 1; A is oxygen, CH2, N-NH2, or the like; when p is 1, B is phenyl, which can have a substituent; when p is 0, B is a condensed ring such as benzisoxazole, which can have a substituent; m is an integer of 1 to 4; and n is an integer of 0 to 5.